×

Eravacycline Data Supporting Activity Against Multidrug-Resistant Gram-Negative Bacteria to be Presented at IDWeek 2015

WATERTOWN, Mass., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, announced today that two posters will be presented at IDWeek 2015 on the company's lead antibiotic candidate, eravacycline. The data presentations will describe eravacycline's activity against bacterial pathogens that cause serious infections, including multidrug-resistant Gram-negative bacteria, and the susceptibility of recent anaerobic isolates to eravacycline and comparators. IDWeek 2015 is being held October 7 - 11 in San Diego, California.

The details for the eravacycline data presentations at IDWeek 2015 are as follows:

Session Number: 130. Antimicrobial Agents: Novel Agents
Presentation Title: Activity of Eravacycline Against Anaerobic Bacteria Collected in 2013-14
Date and Time: Friday, October 9 from 12:30 – 2:00 pm PDT
Presentation Number: 784
https://idsa.confex.com/idsa/2015/webprogram/Paper50966.html

Session Number: 130. Antimicrobial Agents: Novel Agents
Presentation Title: Activity of Eravacycline Against North American and European Enterobacteriaceae, Including Multidrug-Resistant Isolates, Collected in 2013-14
Date and Time: Friday, October 9 from 12:30 – 2:00 pm PDT
Presentation Number: 780
https://idsa.confex.com/idsa/2015/webprogram/Paper50973.html

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). This program includes two phase 3 clinical trials: IGNITE1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE2 for the indication of complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. In addition to eravacycline, Tetraphase's pipeline includes two preclinical antibiotic candidates, TP-271 and TP-6076. Please visit www.tphase.com for more company information.

CONTACT: Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 tdahlman@tphase.com Argot Partners Susan Kim 212-600-1902 susan@argotpartners.com Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 mikebeyer@sambrown.com

Source:Tetraphase Pharmaceuticals